Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954917 | 0.81 | DAO (0.48) | HSD17B10GAAPKMALOX15CYP1A2 | |
| SCHEMBL30142685 | 0.79 | CYP2C19 (0.49) | HSD17B10GAAPKMALOX15CYP1A2 | |
| SCHEMBL24073681 | 0.79 | CYP2C19 (0.49) | HSD17B10GAAPKMALOX15CYP1A2 | |
| SCHEMBL14496948 | 0.78 | GPR35 (0.46) | HSD17B10GAAPKMALOX15HPGD | |
| SCHEMBL208453 | 0.77 | GPR35 (0.44) | HSD17B10GAAPKMALOX15MAPT | |
| SCHEMBL14584377 | 0.77 | HSD17B10 (0.75) | HSD17B10GAAPKMALOX15CYP1A2 | |
| SCHEMBL24188302 | 0.76 | HSD17B10 (0.67) | HSD17B10GAAPKMALOX15CYP1A2 | |
| SCHEMBL15893702 | 0.76 | GAA (0.41) | HSD17B10GAAPKMALOX15MAPT | |
| SCHEMBL210529 | 0.76 | GPR35 (0.44) | HSD17B10GAAPKMALOX15HPGD | |
| SCHEMBL11191679 | 0.75 | HSD17B10 (0.72) | HSD17B10GAAPKMALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185570-B1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2024-10-09 | — | — | EP | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4185570-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| CN-105440051-B | A kind of thiophene pyridine derivate for the treatment of tuberculosis | 重庆医药工业研究院有限责任公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-105440051-A | Antituberculosis thienopyridine derivatives | CHONGQING PHARM RES INST CO | 2016-03-30 | — | — | CN | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2588468-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2588468-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-7411074-B2 | Process and intermediates for the preparation of the thienopyrrole derivatives | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| CN-100378106-C | Process and intermediates for the preparation of the thienopyrrole derivatives | ASTRAZENECA AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| CN-101031566-A | Proline derivatives | MERCK PATENT GMBH (DE) | 2007-09-05 | — | — | CN | disclosed |
| US-20060035953-A1 | Cyclizing an N-carboxymethyl-N-alkanoyl-3-formyl-2-thiophenylamine and optionally amidating the product | ASTRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1688587-A | Process and intermediates for preparing thienopyrrole derivatives | ASTRAZENECA AB (SE) | 2005-10-26 | — | — | CN | disclosed |
| EP-1549654-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF THIENOPYRROLE DERIVATIVES | Astrazeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031194-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF THE THIENOPYRROLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | AVPR1A, AVPR1B, AVPR2 | HSD17B10 3827/4885GAA 4526/4885PKM 3194/4885 |
| US-20060035953-A1 | Cyclizing an N-carboxymethyl-N-alkanoyl-3-formyl-2-thiophenylamine and optionally amidating the product | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, ADCY7 | HSD17B10 1012/4885GAA 3665/4885PKM 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.